Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 831 to 840 of 2636 total matches.

Cephalosporins for Patients with Penicillin Allergy

   
The Medical Letter on Drugs and Therapeutics • Dec 24, 2012  (Issue 1406)
a penicillin.1 HISTORY OF ALLERGY — Patients with a history of an IgE-mediated reaction to a penicillin ...
Only a small minority of patients who say they are allergic to penicillin will have a reaction if they take a penicillin.
Med Lett Drugs Ther. 2012 Dec 24;54(1406):101 |  Show IntroductionHide Introduction

Regorafenib (Stivarga) for Metastatic Colorectal Cancer and GIST (online only)

   
The Medical Letter on Drugs and Therapeutics • Apr 29, 2013  (Issue 1415)
(GIST). Grade 3 or higher adverse effects occur in about 50% of patients. o 1. A Grothey et al ...
Regorafenib (Stivarga – Bayer), a multikinase inhibitor, has been approved by the FDA for treatment of patients with metastatic colorectal cancer previously treated with multiple other regimens specified in the labeling. It has also been approved for use in treatment-refractory, locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST).
Med Lett Drugs Ther. 2013 Apr 29;55(1415):36 |  Show IntroductionHide Introduction

Drugs for COPD

   
The Medical Letter on Drugs and Therapeutics • Sep 02, 2024  (Issue 1710)
for Chronic Obstructive Lung Disease) guidelines for treatment of COPD were updated recently.1 Treatment ...
The main goals of treatment of chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, prevent disease progression, and reduce mortality. GOLD (Global Initiative for Chronic Obstructive Lung Disease) guidelines for treatment of COPD were updated recently. Treatment of acute exacerbations is not discussed here. Drugs available for treatment of COPD are listed in Tables 1 and 3.
Med Lett Drugs Ther. 2024 Sep 2;66(1710):137-44   doi:10.58347/tml.2024.1710a |  Show IntroductionHide Introduction

In Brief: Two Intranasal Corticosteroid HFA Aerosols for Allergic Rhinitis (online only)

   
The Medical Letter on Drugs and Therapeutics • Oct 15, 2012  (Issue 1401)
formulations may be better tolerated. Table 1. Beclomethasone and Ciclesonide for Treatment of Allergic ...
The FDA has approved 2 intranasal HFA (hydrofluoroalkane) aerosols of the corticosteroids beclomethasone dipropionate (Qnasl – Teva Respiratory) and ciclesonide (Zetonna – Sunovion) for once-daily treatment of seasonal and perennial allergic rhinitis. They are the first HFA nasal steroids to become available in the US (HFA propellants do not deplete the ozone layer). Both drugs are already available for these indications as aqueous nasal sprays. Aqueous ("wet") formulations can cause adverse effects such as postnasal drip, moist feeling in the nose, strong odor, and bitter aftertaste,...
Med Lett Drugs Ther. 2012 Oct 15;54(1401):84 |  Show IntroductionHide Introduction

Elderberry for Influenza

   
The Medical Letter on Drugs and Therapeutics • Feb 25, 2019  (Issue 1566)
strains in vitro.1-3 In two small studies (conducted outside the US), adults with influenza A or B virus ...
Patients may ask about taking elderberry for prevention and treatment of influenza. Products containing elderberry are promoted for relief of cold and flu symptoms and as an immune system booster.
Med Lett Drugs Ther. 2019 Feb 25;61(1566):32 |  Show IntroductionHide Introduction

Drugs for Opioid Use Disorder

   
The Medical Letter on Drugs and Therapeutics • Sep 04, 2023  (Issue 1684)
, more than in any previous year.1 Several guidelines on the management of opioid use disorder ...
Opioid use disorder is a chronic, relapsing disease with physical and psychiatric components. It is associated with economic hardship, social isolation, incarceration, increased rates of blood-borne infections such as HIV and viral hepatitis, adverse pregnancy outcomes, and increased mortality. According to the NIH, there were 80,411 deaths involving an opioid in the US in 2021, more than in any previous year. Several guidelines on the management of opioid use disorder are available; all recommend maintenance pharmacotherapy as the standard of care.
Med Lett Drugs Ther. 2023 Sep 4;65(1684):137-44   doi:10.58347/tml.2023.1684a |  Show IntroductionHide Introduction

Comparison Table: Drugs for Parkinson's Disease (online only)

   
The Medical Letter on Drugs and Therapeutics • Feb 22, 2021  (Issue 1618)
in blister packs; a new inhaler should be used with each new carton 84 mg inhaled 1-5x/day prn iFDA ...
View the Comparison Table: Drugs for Parkinson's Disease
Med Lett Drugs Ther. 2021 Feb 22;63(1618):e1-9 |  Show IntroductionHide Introduction

Teduglutide Injection (Gattex) for Short Bowel Syndrome

   
The Medical Letter on Drugs and Therapeutics • Apr 15, 2013  (Issue 1414)
and often experience diarrhea, weight loss, malnutrition and dehydration.1 SBS is the most common diagnosis ...
The FDA has approved teduglutide (te due’ gloo tide; Gattex – NPS), a recombinant DNA analog of glucagon-like peptide-2 (GLP-2), for treatment of short bowel syndrome (SBS) in adults who are dependent on parenteral support.
Med Lett Drugs Ther. 2013 Apr 15;55(1414):29-30 |  Show IntroductionHide Introduction

Drugs for MRSA Skin and Soft-Tissue Infections

   
The Medical Letter on Drugs and Therapeutics • May 12, 2014  (Issue 1442)
of the US.1,2 Community-associated MRSA usually causes furunculosis, purulent cellulitis, and abscesses ...
Methicillin-resistant Staphylococcus aureus (MRSA), which was traditionally a nosocomially-acquired organism but now frequently occurs in the absence of healthcare exposure, is the predominant cause of suppurative skin and soft-tissue infections in many parts of the US. Community-associated MRSA usually causes furunculosis, purulent cellulitis, and abscesses, but necrotizing fasciitis, necrotizing pneumonia, and sepsis can also occur.
Med Lett Drugs Ther. 2014 May 12;56(1442):39-40 |  Show IntroductionHide Introduction

Carbidopa/Levodopa Extended-Release Capsules (Rytary)

   
The Medical Letter on Drugs and Therapeutics • Apr 27, 2015  (Issue 1467)
for symptomatic relief of PD.1 It has been available for many years as immediate- and sustained-release tablets ...
The FDA has approved a new formulation of carbidopa/levodopa (Rytary – Impax) in extended-release capsules for treatment of Parkinson’s disease (PD).
Med Lett Drugs Ther. 2015 Apr 27;57(1467):59-60 |  Show IntroductionHide Introduction